Bullboard - Stock Discussion Forum Arch Biopartners Inc V.ARCH

Alternate Symbol(s): ACHFF

Technology Scientific & Technical Instruments

Arch Biopartners Inc. is a late-stage clinical trial company focused on preventing acute kidney injury. The Company is developing a platform of new drugs to prevent inflammation injury in the kidneys, lungs and liver via the dipeptidase-1 (DPEP1) pathway and are relevant for many common injuries and diseases where organ inflammation is an unmet problem. The Company’s lead drug candidate is... see more

Add To Watchlist

Bullboard (TSXV:ARCH)

View:

Post by Viking2233on Nov 24, 2024 3:41pm

Silence Continues ………

But so does the nefarious shorting algorithms! In my humble opinion the lack of communication and updates, just plays into the hands of those shorting. I ...more

249

Post by Viking2233on Nov 17, 2024 5:28pm

Nothing but Silence

Arch update Well I wish I had something positive to report. I only have my observations and opinions. We are 9 months into dosing in Turkey at 5 sites. Arch management reluctant ...more

254

(0)
•••

Post by PressReleaseon Nov 11, 2024 7:30am

New Press Release - Arch Biopartners Announces Dosing of First Patient in Canada in the Phase II Trial for LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury

TORONTO, Nov. 11, 2024 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today that patient recruitment and dosing have begun in Canada for the Phase II trial for LSALT peptide targeting the prevention and treatment of cardiac...read article.

Comment by Viking2233on Oct 31, 2024 9:23pm

RE:Top 10 Undervalued Healthcare Sector Stocks

Thanks for this River, I have been saying this for months. We are ready to launch, glad I am not yhe only one who can see this!

153

Discussion

Post by Riverfolkon Oct 31, 2024 6:25pm

Top 10 Undervalued Healthcare Sector Stocks

Globe and Mail Article

108

Discussion

Post by Viking2233on Oct 29, 2024 3:18pm

Connecting the dots

1. Been dosing at 5 Turkish sites for 9 months now. Silence from management but no news in this case could be great news as no adverse reactions reported. 2. How many patients dosed? Nobody ...more

157

Post by Viking2233on Oct 27, 2024 7:57pm

Stockholm Conference

Some interesting facts for consideration. The Stockholm conference runs from November 4 to 13. This is a 9 day conference that we are presenting at. I wonder who we are sending and how many days will ...more

200

Post by Viking2233on Oct 23, 2024 12:11pm

California Conference

Well today marks conference number 1 that Arch is attending. I errored in my previous post stating they were presenting, in fact they are simply attending but hopefully networking aggressively. That ...more

205

Post by Viking2233on Oct 17, 2024 6:33am

Is the end of trial near…..

Arch manangement announced on X yesterday that it will be presenting at 2 conferences starting Oct 23 in San Diego California and in November in Stockholm Sweden. Now one thing we know is Arch CEO is ...more

369

(0)
•••

Post by PressReleaseon Oct 15, 2024 6:23pm

New Press Release - Arch Biopartners Arranges Non-Brokered Private Placement

TORONTO, Oct. 15, 2024 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF) today announced it has arranged a non-brokered private placement offering of 290,323 common shares priced at $1.55 per common share (the “Common Shares”) for gross...read article.

Post by Viking2233on Oct 14, 2024 7:51pm

5 Turkish Sites Dosing

At some point and time the markets will finally wake up and realize that Arch has been dosing at 5 sites for almost 8 months. We have no idea how many patients have been dosed but we know that there ...more

189

Post by Viking2233on Oct 06, 2024 5:21pm

7 Months …..

How long does it take in Canada to get ethics approval and provincial approval for drug trial????? We have FDA and Health Canada approval plus we have been dosing in Turkey at 5 sites with no adverse ...more

268

(0)
•••

Post by PressReleaseon Oct 03, 2024 7:45am

New Press Release - Closes Units for Debt Settlement

TORONTO, Oct. 03, 2024 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF) announced today that the Company has closed a transaction that was previously announced on September 26, 2024 to settle an aggregate total of $2,600,000 of principal...read article.

Post by Viking2233on Sep 28, 2024 11:18am

Algo’s taking a break

Nice to see share price finally moving in the right direction. It's simply amazing how the share price reacts when the shorts take a pause. We are almost 8 months into dosing at 5 sites in Turkey ...more

456

(0)
•••

Post by PressReleaseon Sep 26, 2024 8:46am